Amphastar Pharmaceuticals, Inc. Stock

Equities

AMPH

US03209R1032

Pharmaceuticals

Real-time Estimate Cboe BZX 12:26:17 2024-06-03 pm EDT 5-day change 1st Jan Change
42.86 USD +1.24% Intraday chart for Amphastar Pharmaceuticals, Inc. +1.97% -30.80%
Sales 2024 * 752M Sales 2025 * 843M Capitalization 2.07B
Net income 2024 * 192M Net income 2025 * 216M EV / Sales 2024 * 3.32 x
Net Debt 2024 * 423M Net Debt 2025 * 220M EV / Sales 2025 * 2.72 x
P/E ratio 2024 *
10.9 x
P/E ratio 2025 *
9.6 x
Employees 1,761
Yield 2024 *
-
Yield 2025 *
-
Free-Float 63.33%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Slightly Higher Late Afternoon MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon MT
Amphastar Pharmaceuticals Gains US FDA Approval for Generic Bronchospasm Drug MT
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol CI
Transcript : Amphastar Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM
Transcript : Amphastar Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 EPS $1.04, vs. Street Est of $0.79 MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 Revenue $171.8M, vs. Street Est of $174.7M MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
Transcript : Amphastar Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
More news
1 day+0.50%
1 week-2.15%
1 month-0.77%
3 months-8.42%
6 months-26.92%
Current year-31.56%
More quotes
1 week
41.41
Extreme 41.41
43.50
1 month
41.21
Extreme 41.21
46.62
Current year
38.43
Extreme 38.43
65.92
1 year
38.43
Extreme 38.43
67.66
3 years
17.56
Extreme 17.56
67.66
5 years
12.33
Extreme 12.325
67.66
10 years
8.32
Extreme 8.32
67.66
More quotes
Managers TitleAgeSince
Founder 74 96-02-28
Chief Executive Officer 77 96-02-28
Director of Finance/CFO 56 14-03-31
Members of the board TitleAgeSince
Director/Board Member 67 03-01-31
Director of Finance/CFO 56 14-03-31
Director/Board Member 64 01-05-31
More insiders
Date Price Change Volume
24-06-03 42.92 +1.39% 143 486
24-05-31 42.33 +0.43% 352,375
24-05-30 42.15 +1.22% 148,145
24-05-29 41.64 -0.80% 201,666
24-05-28 41.98 -2.97% 377,085

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
42.33 USD
Average target price
62.6 USD
Spread / Average Target
+47.89%
Consensus